Effect of reactive site loop elongation on the inhibitory activity of C1-inhibitor

被引:3
作者
Bos, IGA
Lubbers, YTP
Eldering, E
Abrahams, JP
Hack, CE
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Immunopathol, Sanquin Res CLB, NL-1066 CX Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands
[4] Leiden Inst Chem, NL-2333 CC Leiden, Netherlands
[5] Vrije Univ Amsterdam, Dept Clin Chem, Med Ctr, NL-1081 HV Amsterdam, Netherlands
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2004年 / 1699卷 / 1-2期
关键词
C1-Inh; complement; serpin; reactive site loop; inhibition;
D O I
10.1016/j.bbapap.2004.02.006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serine protease inhibitor C1-Inhibitor (C1-Inh) inhibits several complement- and contact-system proteases, which play an important role in inflammation. C1-Inh has a short reactive site loop (RSL) compared to other serpins. RSL length determines the inhibitory activity of serpins. We investigated the effect of RSL elongation on inhibitory activity of C1-Inh by insertion of one or two alanine residues in the RSL. One of five mutants had an increased association rate with kallikrein, but was nevertheless a poor inhibitor because of a simultaneous high stoichiometry of inhibition (>10). The association rate of the other variants was lower than that of wild-type C1-Inh. These data suggest that the relatively weak inhibitory activity of C1-Inh is not the result of its short RSL. The short RSL of C1-Inh has, surprisingly, the optimal length for inhibition. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:139 / 144
页数:6
相关论文
共 23 条
[1]  
AULAK KS, 1993, J BIOL CHEM, V268, P18088
[2]  
BEATTY K, 1980, J BIOL CHEM, V255, P3931
[3]   HUMAN C1BAR INHIBITOR - PRIMARY STRUCTURE, CDNA CLONING, AND CHROMOSOMAL LOCALIZATION [J].
BOCK, SC ;
SKRIVER, K ;
NIELSEN, E ;
THOGERSEN, HC ;
WIMAN, B ;
DONALDSON, VH ;
EDDY, RL ;
MARRINAN, J ;
RADZIEJEWSKA, E ;
HUBER, R ;
SHOWS, TB ;
MAGNUSSON, S .
BIOCHEMISTRY, 1986, 25 (15) :4292-4301
[4]   The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant [J].
Bos, IGA ;
Lubbers, YTP ;
Roem, D ;
Abrahams, JP ;
Hack, CE ;
Eldering, E .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (32) :29463-29470
[5]   Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor [J].
Bos, IGA ;
de Bruin, EC ;
Karuntu, YA ;
Modderman, PW ;
Eldering, E ;
Hack, CE .
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, 2003, 1648 (1-2) :75-83
[6]   Structural and functional aspects of C1-Inhibitor [J].
Bos, IGA ;
Hack, CE ;
Abrahams, JP .
IMMUNOBIOLOGY, 2002, 205 (4-5) :518-533
[7]   Protein engineering of chimeric Serpins: an investigation into effects of the serpin scaffold and reactive centre loop length [J].
Bottomley, SP ;
Stone, SR .
PROTEIN ENGINEERING, 1998, 11 (12) :1243-1247
[8]  
Caliezi C, 2000, PHARMACOL REV, V52, P91
[9]   PLAKALBUMIN, ALPHA-1-ANTITRYPSIN, ANTITHROMBIN AND THE MECHANISM OF INFLAMMATORY THROMBOSIS [J].
CARRELL, RW ;
OWEN, MC .
NATURE, 1985, 317 (6039) :730-732
[10]  
CORMACK B, 2000, CURRENT PROTOCOLS MO, V1